Prognostic Factors of Immunotherapy in Metastatic Renal Cell Carcinoma

Medical Oncology

Volumn 20, Issue 4, 2003, Pages 325-334

  Padrik, Peeter ^a  

^a TARTU UNIVERSITY CLINICS   (Estonia)

Author keywords

Biological response modifiers; Immunotherapy; Kidney neoplasms; Prognosis; Risk

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; C REACTIVE PROTEIN; CALCIUM; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 2; ISOTRETINOIN; LACTATE DEHYDROGENASE; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ANXIETY; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; NEUTROPHIL; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; WEIGHT REDUCTION;

BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; PROGNOSIS;

EID: 0346102836     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:4:325     Document Type: Review

References (42)

1. Parkin DM, Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49:33-64.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
4. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691-1696.
5. Savage PD. Renal cell carcinoma. Curr Opin Oncol 1996; 8:247-251.
6. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865-875.
7. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22:42-60.
8. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19:1541-1543.
9. Motzer RJ. Renal cell carcinoma: progress against an elusive tumor. Semin Oncol 2000; 27:113-114.
10. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27:177-186.
11. Pyrhönen S, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859-2867.
12. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353:14-17.
13. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27:187-193.
14. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6:S55-57.
15. Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696.
16. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000:CD001425.
17. Negrier S, et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000; 6.-S93-98.
18. Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000; 27:204-212.
19. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19:148-154.
20. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136:376-379.
21. de Forges A, et al. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 1988; 4:149-154.
22. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310-7313.
23. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994; 30A:1310-1314.
24. Fossa S, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995; 76:286-290.
25. Citterio G, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997; 31:286-291.
26. Takashi M, Kawai T, Murase T, Wakai K, Ohno Y. Multivariate evaluation of prognostic determinants for renal cell carcinomas which are metastatic at initial diagnosis. Int Urol Nephrol 1997; 29:291-300.
27. Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
28. Motzer RJ, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:1928-1935.
29. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000; 34:246-251.
30. Palmer PA, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3:475-480.
31. Jones M, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993; 8:275-288.
32. Lissoni P, et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 1994; 51:59-62.
33. Canobbio L, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. J Cancer Res Clin Oncol 1995; 121:753-756.
34. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:35-40.
35. Lopez Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155:19-25.
36. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
37. Negrier S, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13:1460-1468.
38. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348-353.
39. Elias L, Hunt WC. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy. Oncology 2001; 61:91-101.
40. Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659.
41. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-970.
42. Mian BM, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167:65-70.